Heartware International Inc

0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS

Case Summary
Company Name: Heartware International Inc
Stock Symbol : NASDAQ: HTWR
Class Period Start: 06/10/2014
Class Period End: 01/11/2016
Lead Plaintiff motion: 03/22/2016
Date Filed: 01/22/2016
Type of Case: Securities Class Action
Court: U.S. District Court for the Southern District of New York
Summary:

Thieler Law Corp advises investors with losses exceeding $100,000 of the March 22, 2016 lead plaintiff deadline in a class action lawsuit filed against Heartware International Inc (NASDAQ: HTWR) (“Heartware International” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Heartware International securities between June 10, 2014 and January 11, 2016, have until March 22, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Heartware International securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Heartware International wrongly assured investors that the Company had sufficiently addressed numerous manufacturing and other regulatory failures at the Company's sole manufacturing facility, and that these failures, created no risk to the clinical trials or timely approval of a pump (MVAD) that the Company is presently developing. The failures had been identified by the U.S. Food and Drug Administration in a Warning Letter.

On September 9, 2015, Heartware International disclosed that it had “paused its MVAD clinical trial to address an MVAD controller manufacturing process issue.”

On October 13, 2015, Heartware International disclosed certain adverse events in clinical trials of the Company’s MVAD products, and stated that the MVAD clinical trials may not be re-initiated.

On January 11, 2016 Heartware International disclosed that issues with MVAD had resulted in serious adverse events in nearly half of the patients so far implanted with the device and that the trial would be delayed indefinitely.

On this news, NASDAQ: HTWR shares declined, causing investors damages.

If you were negatively impacted by your investment in Heartware International securities between June 10, 2014 and January 11, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185

 

Transactions
Buy date (mm/dd/yyyy) Number of shares Price per share
Sell date (mm/dd/yyyy) Number of shares Price per share
Please wait...